Nykode Therapeutics - Quarterly report Q1 2024
May 14 2024 - 1:00AM
Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage
biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced its unaudited
financial results for the first quarter of 2024.
The financial report can be accessed in the
Investors section of the Company’s website:
https://nykode.com/investors/financial-reports-and-presentations.
The Company will host a webcast presentation at
4 p.m. CET / 10 a.m. ET. A live and archived webcast of the
presentation can be accessed in the Investors section of the
Company’s website and on the following link:
https://event.webcasts.com/starthere.jsp?ei=1670178&tp_key=4faf9c3758
About Nykode TherapeuticsNykode
Therapeutics is a clinical-stage biopharmaceutical company
dedicated to the discovery and development of novel immunotherapies
with a focus on the treatment of cancer and autoimmune diseases.
Nykode’s modular vaccine technology specifically targets antigens
to antigen presenting cells (APC), which have been shown to induce
a broad, strong and long-lasting antigen specific immune response
in cancer, which correlates with clinical responses.
Nykode’s lead product candidates are VB10.16, a
therapeutic vaccine for the treatment of HPV16 induced malignancies
which demonstrated favorable safety and efficacy results from its
Phase 2 trial for the treatment of cervical cancer. VB10.16 is
being expanded into multiple trials for treatment of head and neck
cancer and cervical cancer. VB10.NEO, an individualized cancer
neoantigen vaccine, is exclusively out-licensed to Genentech, a
member of the Roche Group.
The Company’s partnerships include Genentech
within oncology and a multi-target collaboration with Regeneron in
oncology and infectious diseases.
Nykode is also utilizing its APC-targeted
technology to create an inverse vaccine platform for the potential
use in autoimmune disorders, organ transplant rejections, anti-drug
antibody reactions and allergy.
Nykode Therapeutics’ shares are traded on the
Oslo Stock Exchange (OSE: NYKD). Further information about Nykode
Therapeutics can be found at http://www.nykode.com.
Contact:Alexandra Deschner, Head of IRNykode
Therapeutics ASAIR@nykode.com
Nykode Therapeutics ASAOslo Science
ParkGaustadalléen 21N-0349 Oslo, Norway
Forward-looking statements for Nykode
Therapeutics
This announcement and any materials distributed
in connection with this announcement may contain certain
forward-looking statements. By their nature, forward-looking
statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events
and circumstances that may not prove accurate. A number of material
factors could cause actual results and developments to differ
materially from those expressed or implied by these forward-looking
statements.
A PDF attachment accompanying this announcement
is available
at: http://ml-eu.globenewswire.com/Resource/Download/7a1cab79-2530-4ec2-8392-9b16d7360e18